drugset / Trial / NCT04326881
A Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects
RandomizedParallel-groupOpen-labelOther
Summary
This study will be a single-center, randomized, parallel, open-label, single dosing bridging study in healthy subjects to evaluate the pharmacokinetics and safety of two formulations of SHR-1314.
Timeline
- Start
- 2020-04-07
- Primary completion
- 2020-07-07
- Completion
- 2020-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | vunakizumab | Protein / enzyme biologic | 240 mg | Subcutaneous |
Indications
No indication recorded.